MCV4
Phase 3Biologic
CanSino Biologics Inc.MCV4 is one of 109 biologic programs targeting Influenza. It is currently in Phase 3.
3
Indications
6
Total Trials
3
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
127 competitors in Clinical Trial
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Avelox
BayerPhase 3
Paraplatin
AAvyxa
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 3
Potassium Iodide
MMeda Pharmaceuticals
Phase 3
Ablysinol
CSL BehringPhase 3
Nascobal
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Grafapex
MMedexus Pharma, Inc.
Phase 2
MCV4
CanSino Biologics Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Clinical Trial2 trials
Immunogenicity1 trial
Influenza1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MCV4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company